▟ Vinebot intrinsic value, daily

← back

MTD Mettler Toledo

pharma · valued with opus medium conviction · deep-dived 2026-10-21

HOLD
Intrinsic value$835.28
Price (at call)$1,634.01
Margin of safety -48.9%
vs market (rating basis) -10.4%

World-class weighing franchise, but the price already assumes a decade of flawless growth and margins.

The story

Mettler-Toledo is the global leader in precision weighing and lab and industrial instruments. Its moat rests on a large installed base, a service and consumables business that brings in recurring revenue, and pricing power built on its Spinnaker sales and productivity programs. It is a mature, cash-generative franchise. Recent organic growth has been weak (about 1% 5-year CAGR, hurt by the post-COVID lab and China slump), but long-run mid-single-digit growth should resume as pharma and biotech capex, automation, and reshoring recover. Heavy buybacks fund shareholder returns rather than reinvestment.

A 12-year horizon fits a durable franchise with sticky service revenue. Growth starts at 6%, reflecting lab demand recovery plus pricing, and fades to 4% in the terminal year, below the risk-free rate. The margin edges up from 28% to 31% through pricing and productivity, not to a peak. Sales-to-capital of 2.5 reflects asset-light incremental growth on top of a roughly 45% ROIC. Even with generous drivers, value lands well below the price: the market is paying about 36x NOPAT, which assumes near-perfect execution.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth4.0%
Forecast horizon12y
Target operating margin31.0%
Years to target margin5
Sales-to-capital2.50
Beta0.95
Failure probability0.0%
Cost of capital (WACC)9.2%
Terminal WACC9.4%

Valuation bridge

PV of explicit FCFF9.26B
PV of terminal value9.56B
Equity value16.74B
÷ shares → per share$835.28

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 4.38B 6.0% 28.8% 1.04B 99.21M 945.77M 866.48M
2 4.64B 5.8% 29.3% 1.13B 101.98M 1.03B 860.46M
3 4.90B 5.6% 29.9% 1.21B 104.54M 1.11B 852.54M
4 5.17B 5.5% 30.4% 1.30B 106.87M 1.20B 842.79M
5 5.44B 5.3% 31.0% 1.40B 108.94M 1.29B 831.30M
6 5.71B 5.1% 31.0% 1.47B 110.73M 1.36B 802.60M
7 6.00B 4.9% 31.0% 1.54B 112.21M 1.43B 773.55M
8 6.28B 4.7% 31.0% 1.61B 113.36M 1.50B 744.26M
9 6.56B 4.5% 31.0% 1.69B 114.15M 1.57B 714.84M
10 6.85B 4.4% 31.0% 1.76B 114.57M 1.65B 685.39M
11 7.14B 4.2% 31.0% 1.83B 114.59M 1.72B 656.01M
12 7.42B 4.0% 31.0% 1.91B 114.19M 1.79B 626.80M

Key risks

  • Pharma and biotech capex and China lab demand stay depressed, keeping organic growth near 1-3%
  • Tariffs, FX, and input costs squeeze margins that are already near the high end of the industry
  • Multiple compression: a 36x NOPAT valuation leaves no room for a growth miss, and leverage from buybacks increases downside

Catalysts

  • Lab and bioprocessing instrument replacement cycle plus GLP-1/reshoring capex driving a return to 6-8% organic growth
  • Continued buybacks and Spinnaker/SternDrive margin gains lifting EPS above expectations

History

DatePriceIntrinsicMoSRating
2026-10-21$1,634.01 $835.28 -48.9% HOLD
2026-09-17$1,378.69 $568.53 -58.8% HOLD
2026-08-17$1,419.02 $599.40 -57.8% HOLD
2026-07-14$1,299.53 $585.45 -54.9% HOLD
2026-06-23$1,156.64 $601.89 -48.0% HOLD